Climb Bio develops antibody medicines for immune system diseases, including rare kidney and blood disorders. It last closed at $9.78 on Nov 17, down 1.61% on the day. The average 12-month price target from 7 analysts is $28.14 (+187.8% from the last close), with a high of $32.00 and a low of $25.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell).
Each firm's latest rating on CLYM in the past 90 days
Average 12-month target
$28.14
▲ 187.8% upside
Based on 7 analysts who set a price target on CLYM in the past 90 days. The average target is $28.14, with a high of $32.00 and a low of $25.00, compared with the last close of $9.78.
Low $25.00Avg $28.14High $32.00
Blue marker: last close $9.78
Highest target$32.00
Average target$28.14
Lowest target$25.00
Latest rating changes
WedbushTarget raised
Nov 6Buy$20 → $27
Deutsche BankInitiated
Oct 20Buy$28
OppenheimerMaintained
Sep 8Buy$25
HC Wainwright & Co.Target raised
Sep 8Buy$24 → $30
B. Riley SecuritiesReiterated
Sep 4Buy$30
Date
Firm
Action
Rating
Price target
Nov 6
Wedbush
Target raised
Buy
$20 → $27
Oct 20
Deutsche Bank
Initiated
Buy
$28
Sep 8
Oppenheimer
Maintained
Buy
$25
Sep 8
HC Wainwright & Co.
Target raised
Buy
$24 → $30
Sep 4
B. Riley Securities
Reiterated
Buy
$30
Loading…
Technical Analysis
CLYM · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend
The stock is 5% below its 20 day and 16% below its 50 day average. It is 10% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the swing low (Oct 19) at $9.61, and the nearest resistance the Pivot at $9.86.
Short trendBearish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 9.6%/day
Key levels
$18.3352 week high+87.4%
$12.72100 day average+30.1%
$11.3450 day average+16.0%
$10.72200 day average+9.6%
$10.55Swing high (Oct 29)+7.9%
$10.34Pivot R1+5.7%
$10.2320 day average+4.6%
$9.86Pivot+0.8%
$9.78Last close
$9.61Swing low (Oct 19)−1.7%
$9.29Pivot S1−5.0%
$1.6452 week low−83.2%
Indicators
RSI (14)
44.05
Middle of its range
Neutral
MACD
-0.19
Above its signal line
Bullish
Stochastic
39.0
Middle of its range
Neutral
ADX (14)
27.0
Trending down
Williams %R
-67.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-43.4
Oversold below −100, overbought above 100
Neutral
Rate of change
+0.3%
Change over 10 sessions
Bullish
ATR (14)
$0.93
Typical daily range, 9.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 19.5%/day
Key levels
$18.3352 week high+87.4%
$12.72100 day average+30.1%
$11.3450 day average+16.0%
$10.72200 day average+9.6%
$10.55Swing high (Oct 29)+7.9%
$10.34Pivot R1+5.7%
$10.2320 day average+4.6%
$9.86Pivot+0.8%
$9.78Last close
$9.61Swing low (Oct 19)−1.7%
$9.29Pivot S1−5.0%
$1.6452 week low−83.2%
Indicators
RSI (14)
43.04
Middle of its range
Neutral
MACD
-0.08
Below its signal line
Bearish
Stochastic
16.8
Near the bottom of its range
Oversold
ADX (14)
26.8
Trending down
Williams %R
-86.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-99.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−31.4%
Change over 10 sessions
Bearish
ATR (14)
$1.90
Typical daily range, 19.5% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for CLYM
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CLYM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in CLYM in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CLYM is in one of them and how their past CLYM trades turned out.
Climb Bio is a biotechnology company based in Wellesley Hills, Massachusetts. It is developing antibody medicines for diseases in which the immune system attacks the body. Its lead candidate, budoprutug, is designed to deplete a type of B cell and is being tested in patients with membranous nephropathy, a rare kidney disease, as well as immune thrombocytopenia and lupus. A second candidate, CLYM116, targets a protein linked to IgA nephropathy, a kidney condition. Its candidates are still in clinical trials and are not yet sold.